Welcome to our dedicated page for NEXGEL SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NexGel, Inc. filings document the formal disclosures of a Nasdaq-listed operating company focused on hydrogel-based healthcare, beauty and OTC products. Recent 8-K reports cover material definitive agreements, an exclusive license and asset purchase for regenerative biomaterial products, convertible-note financing, and capital-structure terms tied to common stock, notes and warrants.
The filings also record board and financial officer changes, employment and compensation arrangements, Nasdaq listing-compliance notices, Regulation FD communications, and exhibits to material contracts. These disclosures connect NexGel’s product expansion, financing activity, governance structure and public-company reporting obligations.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported an open-market sale of common stock. He sold 2,000 shares of Common Stock at a price of $0.5859 per share on June 1, 2026. After this transaction, he directly owned 342,692 shares of NEXGEL common stock, so the sale represents a small portion of his overall reported holdings.
NEXGEL, INC. Chief Executive Officer Adam R. Levy reported selling a total of 13,000 shares of Common Stock in open-market transactions over three days. He sold 3,000 shares at $0.5975 per share, 7,000 shares at a weighted average price of $0.6058 per share, and 3,000 shares at $0.6003 per share. Following these sales, he directly holds 344,692 shares of NEXGEL Common Stock, indicating these sales represent a relatively small portion of his overall position.
NexGel, Inc. seeks stockholder approval at its 2026 Annual Meeting for seven proposals, most notably shareholder approval under Nasdaq rules to permit issuance of shares exceeding 19.99% upon conversion of convertible notes and exercise of warrants from its April and May 2026 private financings. The proxy also asks to approve reincorporation from Delaware to Nevada (including authorization of 100,000,000 authorized common shares and a discretionary reverse split authority of 1-for-2 to 1-for-10), fallback Delaware amendments increasing authorized shares from 25,000,000 to 100,000,000, an advisory say-on-pay vote, and ratification of auditors. The proxy discloses Financings that include unsecured convertible notes (initial conversion price $0.60) and warrants (exercise price $0.80), related-party participation, and illustrative dilution tables showing up to 31,900,001 underlying shares at initial prices.
NEXGEL director Henry Scott Robert acquired new derivative securities linked to the company’s common stock. He received a Convertible Promissory Note with an original principal amount of $25,000, which is convertible into up to 41,667 shares of common stock at an initial conversion price of $0.60 per share.
He also received a Warrant to Purchase Common Stock for 20,834 shares at an initial exercise price of $0.80 per share. Both the note and warrant are exercisable at his option, subject to a 4.99% beneficial-ownership limitation and other specified conditions.
NEXGEL director Brian Joseph Kieser bought a $1,000,000 Convertible Promissory Note and received a large stock warrant as part of the same financing. The Note can be converted into up to 1,666,667 shares of common stock at $0.60 per share. The warrant is exercisable for 833,334 shares at $0.80 per share. Both instruments are convertible or exercisable at the holder’s option but are subject to a 4.99% beneficial-ownership limitation on NEXGEL’s outstanding common stock.
NEXGEL, INC. reported that Chief Executive Officer Adam R. Levy acquired derivative securities linked to its common stock. He received a Convertible Promissory Note with an original principal amount of $60,000, which is convertible into up to 100,000 shares of common stock at $0.60 per share. He also received a Warrant to Purchase Common Stock for 50,000 shares at an initial exercise price of $0.80 per share, issued as part of the consideration for purchasing the note. Both the note and warrant are exercisable at any time at his option, subject to a 4.99% beneficial-ownership limitation that restricts conversion or exercise if it would push ownership above that threshold.
NEXGEL, INC. filed a Form 3 identifying Harris Kevin McClain as a director of the company. The data provided shows no reportable purchases, sales, or other transactions in NEXGEL securities, and no derivative positions or holdings are listed in this snapshot.
NEXGEL, INC. director Brian Joseph Kieser has filed an initial ownership report showing indirect derivative positions held through Sequence LifeScience, Inc. The holdings include a warrant to acquire 4,583,334 shares of common stock at an exercise price of 0.8000, expiring on 2031-04-17, and a convertible promissory note convertible into 9,166,667 shares at 0.6000, expiring on 2027-10-17. Both instruments are exercisable or convertible at the holder’s option but are subject to a 4.99% beneficial-ownership limitation and other terms. Kieser is the indirect sole owner of Sequence and may be deemed to share voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.
NexGel, Inc. entered into a private placement of unsecured convertible promissory notes with accredited investors, raising aggregate gross proceeds of $1,210,000. The notes have an aggregate original principal amount of $1,210,000 and are convertible into common stock at an initial price of $0.60 per share.
Investors also received warrants exercisable for an aggregate of 1,008,334 common shares at an exercise price of $0.80 per share, expiring five years from issuance. The company plans to use the net proceeds for working capital. Affiliates purchased $1,085,000 of the offering, including director Brian J. Kieser with $1,000,000, CEO Adam Levy with $60,000, and director Scott Henry with $25,000.
NexGel agreed under a Registration Rights Agreement to file a resale registration statement for the shares underlying the notes and warrants within 75 days of closing and to seek SEC effectiveness within 150 days of the initial filing.